article thumbnail

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

Bio Pharma Dive

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

article thumbnail

What to make of Eisai and Biogen’s latest Alzheimer’s drug data

Bio Pharma Dive

At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits.

Doctor 359
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diabetes advocacy group discourages use of compounded GLP-1 drugs

Bio Pharma Dive

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Pharmacy 301
article thumbnail

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Bio Pharma Dive

But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness. Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations.

Sales 343
article thumbnail

Alzheimer’s doctors see promise, limits in Lilly’s latest drug data

Bio Pharma Dive

While some see the new donanemab results as adding to a “watershed moment” in Alzheimer’s research, others say they reinforce the limitations of so-called anti-amyloid therapies.

Doctors 299
article thumbnail

Obesity drug from Zealand shows potential in early trial

Bio Pharma Dive

Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.

Drugs 284
article thumbnail

After surprise trial failure, ALS doctors brace for one less treatment option

Bio Pharma Dive

Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.

Doctors 313